Glioblastoma
Glioblastoma is a fast-growing and aggressive type of brain tumor that arises from glial cells, often leading to severe symptoms and a poor prognosis.
Glioblastoma Treatment: Lomustine with or without Reirradiation
We are studying whether adding a second round of radiation to lomustine improves survival and quality of life for patients with recurrent glioblastoma. This trial aims to find out if this combination is more effective than lomustine alone.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have a diagnosis of glioblastoma (a type of brain cancer)?
- Are you currently pregnant or breastfeeding?
- Have you had any cancer treatment for recurrent glioblastoma other than surgery?
- Have you had any serious medical conditions that could affect your participation in a study?
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Cecenu®
Lomustin (Ccnu) Medac
Lomustine Medac
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Medizinische Universitaet Innsbruck
Neurology
Innsbruck, Austria
Kepler Universitaetsklinikum GmbH
Neurology
Linz, Austria
Medical University of Vienna
Oncology
Vienna, Austria
Sponsor: European Organisation For Research And Treatment Of Cancer
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.